Attention to the 38th issue of global major clinical new drug varieties

Lipitor, a drug with sales exceeding 100 billion yuan in the first patent period! Plavix, a drug with annual revenue of 9 billion dollars in the patent period! Taiweimei, the world's first H2 receptor antagonist, has promoted a number of "blockbusters" with its epoch-making significance in mechanism! There are also loxuxi, enri, Losec and Viagra This is a name that you know well, and your eyes are red It not only left a heavy stroke in the history of human health code exploration, but also a money tree and a money printing machine "Heavy pound bomb" became a giant company, and the giant company fully defended the "heavy pound bomb" However, to be an original research drug or a generic drug is nothing more than your choice to own or seize the patent rights of the best-selling drugs So, is the patent cliff their disaster or our carnival? New drug R & D is becoming more difficult, and the regulatory threshold is higher and higher, but why is sovaldi out of the world? The good news is frequent, whether the domestic independent R & D of new drugs ushers in the spring In 2015, the world's new drug research and development, we can no longer be a spectator We should pay more attention to R & D and the lifeline of this pharmaceutical enterprise from the beginning to the end We should know that the best-selling drugs must not only be a bunch of molecular formulas, but also have their own genes and personalities On June 27-28, Coship and Thomson Reuters, the world's top information organization, yaozhi.com, kebayuan (Beijing) Biomedical Technology Co., Ltd., Yaodu Jingwei information technology (Beijing) Co., Ltd and Xinkangjie, and the 38th Coship forum organized by Beijing Zitan Management Consulting Co., Ltd will be held in Beijing At that time, several professional information institutions such as yaozhi.com, yaodu.com, Beijing Center of Audit Association and experts from clinical, new drug development, laws and regulations will jointly interpret the current global hot new drug varieties for the pharmaceutical industry Discuss "how to produce heavy bombs" together and how Chinese pharmaceutical companies can use these new "heavy bombs" to win the future Report theme and guests more heavyweight speakers are constantly updating and widely soliciting sponsors and co organizers! Registration for this activity is all online registration link: http://tongxieyi38.eventdove.com seats are limited, please register as soon as possible! Registration system opening time: June 3-27, 2015 registration fee· 2000 yuan / person (signed up before June 15) · 2200 yuan / person (signed up before June 22) · 2400 yuan / person (signed up after June 23) · the fee includes: conference fee, meal fee (lunch on June 27, 2015; lunch on June 28) the same as freehand 2015 member · individual member: free · enterprise member: Free Quota: 3 / enterprise; Consulting Secretariat: 010-52980312 email: tongxieyiclub@sina.com contact: Zhang Mingyue 15101686528 related link: Thomson Reuters is the world's leading professional information service provider Thomson Reuters Life Science Division is committed to providing strong professional information and intelligence solutions for R & D and innovation in the field of life science Combining comprehensive, accurate and timely information with powerful analysis tools, it provides global pharmaceutical enterprises and research institutes with information reporting solutions covering the entire drug life cycle, such as drug research and development, competitive intelligence, clinical trials, policies and regulations, trading cooperation, news and information, patents, etc Through professional information database and in-depth consulting services, help pharmaceutical enterprises and research units to accelerate drug discovery and development, optimize the combination of intellectual property rights of pharmaceutical enterprises, quickly lock authorization and cooperation opportunities, and successfully register and apply to regulatory authorities Its databases such as cortellis, Newport and integrity have become domestic pharmaceutical enterprises' drug research and development, pipeline expansion An important tool for Cooperative Trading Www.yaozh.com, a professional medical technology information service platform, was officially launched in 2009 We are committed to promoting the scientific development and technological progress of the pharmaceutical industry With big data as the core, we provide a package of solutions for the development of the pharmaceutical industry by providing data query, consulting services, technology transactions and third-party service platforms The company has such modules as yaozhiweike, yaozhidata, yaozhimall, yaozhinews, yaozhiforum, etc the yaozhidata integrates global pharmaceutical information, and the independently developed pharmaceutical query system provides one-stop retrieval service, which can comprehensively and quickly retrieve pharmaceutical information at home and abroad Yaodu Jingwei Yaodu Jingwei information technology (Beijing) Co., Ltd (hereinafter referred to as "Yaodu") is committed to providing professional and in-depth pharmaceutical research and development data and resource allocation information "one-stop platform" for relevant professionals in global drug research and development It covers the data and resource information of drug project research, research and development, technical cooperation, investment M & A, talent exchange and other aspects, mainly including 7 + professional sections such as drug R & D data section It also provides customers with comprehensive, in-depth and integrated positioning, evaluation and analysis of biomedical R & D projects, as well as forward-looking information and technical consulting services for drug R & D, providing the driving force for drug R & D As a public institution directly under the Patent Office of the State Intellectual Property Office, the Beijing Center of Audit Association is responsible for the preliminary examination, practical examination, PCT examination of patent applications, as well as providing technical and legal consulting services for enterprises.